{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:26:14Z","timestamp":1787772374873,"version":"build-2784847793"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting toxicity of cancer treatment, yet reliable biomarkers to predict individual susceptibility remain lacking. Germline genetic variation has been widely investigated as a potential contributor to CIPN risk; however, the consistency and clinical utility of these associations remain unclear. We performed a systematic review of genetic association studies evaluating CIPN across neurotoxic chemotherapies. PubMed, Embase, Web of Science, and the Cochrane Library were searched (April 2025) for human studies assessing germline variants in relation to clinician- or patient-reported CIPN. Eligible studies were identified in four major drug classes: vincristine, taxanes, platinum agents, and bortezomib. Study characteristics, phenotyping approaches, ancestry, and variant-level data were extracted, and study quality was assessed using Q-Genie. Meta-analysis was not performed due to substantial heterogeneity in study design and outcome measures. 72 studies were included, predominantly involving cohorts of European ancestry. The most consistently replicated loci were CEP72 and ETAA1 for vincristine-induced neuropathy; EPHA5, FGD4, and FZD3 for taxane-induced neuropathy; and ABC transporter genes and GSTP1 for platinum-induced neuropathy. For bortezomib, associations involving TRPV1, DNA repair pathways, and inflammatory signalling showed emerging but largely non-replicated evidence. Across studies, marked heterogeneity in CIPN definitions, phenotyping instruments, statistical approaches, and effect allele reporting limited comparability and reproducibility. Collectively, these findings indicate that current pharmacogenomic approaches to CIPN are constrained by poor replication, population bias, and inconsistent methodology, which hinder translation into clinically actionable biomarkers. Future progress will require harmonised phenotyping, multi-ancestry genome-wide studies, and integration of functional validation to enable robust risk stratification and precision oncology approaches to CIPN.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>Identifier PROSPERO [CRD42025635757].<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1842379","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:34:09Z","timestamp":1783575249000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Why pharmacogenomic biomarkers for chemotherapy-induced peripheral neuropathy fail: a systematic review of genetic associations, replication, and clinical translation"],"prefix":"10.3389","volume":"17","author":[{"given":"Aditya","family":"Maganti","sequence":"first","affiliation":[{"name":"Medical School, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishara","family":"Rankothge","sequence":"additional","affiliation":[{"name":"Medical School, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Sakadales","sequence":"additional","affiliation":[{"name":"Medical School, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Kok","sequence":"additional","affiliation":[{"name":"School of the Environment (Biological Sciences), The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Britton","sequence":"additional","affiliation":[{"name":"Medical School, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Rao","sequence":"additional","affiliation":[{"name":"Medical School, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Shatunova","sequence":"additional","affiliation":[{"name":"Institute for Molecular Bioscience, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Shimell","sequence":"additional","affiliation":[{"name":"Institute for Molecular Bioscience, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Manuela Rojas","family":"Zambrano","sequence":"additional","affiliation":[{"name":"Institute for Molecular Bioscience, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna B.","family":"Park","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney","place":["Sydney, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Schweitzer","sequence":"additional","affiliation":[{"name":"Mater Centre of Neuroscience, Mater Hospital, Wesley Hospital, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E-Liisa","family":"Laakso","sequence":"additional","affiliation":[{"name":"Mater Research Institute-The University of Queensland","place":["South Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Yengo","sequence":"additional","affiliation":[{"name":"Institute for Molecular Bioscience, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Vetter","sequence":"additional","affiliation":[{"name":"Institute for Molecular Bioscience, The University of Queensland","place":["Brisbane, QLD, Australia"]},{"name":"The School of Pharmacy and Pharmaceutical Sciences, The University of Queensland","place":["Woolloongabba, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Starobova","sequence":"additional","affiliation":[{"name":"Institute for Molecular Bioscience, The University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1089\/gtmb.2021.0014","article-title":"ABCB1 single nucleotide polymorphism genotypes as predictors of paclitaxel-induced peripheral neuropathy in breast cancer","volume":"25","author":"Abdelfattah","year":"2021","journal-title":"Genet. Test. Mol. Biomarkers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1158\/1078-0432.CCR-13-3232","article-title":"Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel","volume":"20","author":"Abraham","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3390\/cancers13051084","article-title":"Genetic predictors of chemotherapy-induced peripheral neuropathy from paclitaxel, carboplatin and oxaliplatin: ncctg\/alliance N08C1, N08CA and N08CB study","volume":"13","author":"Adjei","year":"2021","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/j.1468-1331.2010.02966.x","article-title":"Integrin beta\u20103 L33P: a new insight into the pathogenesis of chronic oxaliplatin\u2010induced peripheral neuropathy?","volume":"17","author":"Antonacopoulou","year":"2010","journal-title":"Euro J Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1046\/j.1365-2141.2003.04430.x","article-title":"CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia","volume":"122","author":"Aplenc","year":"2003","journal-title":"Br. J. Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/cts.12869","article-title":"Pharmacogenomics biomarker discovery and validation for translation in clinical practice","volume":"14","author":"Arbitrio","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.redox.2014.01.006","article-title":"Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy","volume":"2","author":"Areti","year":"2014","journal-title":"Redox Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ctrv.2008.01.003","article-title":"A review on oxaliplatin-induced peripheral nerve damage","volume":"34","author":"Argyriou","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1158\/1078-0432.CCR-12-1590","article-title":"A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101","volume":"18","author":"Baldwin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00280-010-1466-y","article-title":"Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity","volume":"67","author":"Basso","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1742-7843.2011.00802.x","article-title":"Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer","volume":"110","author":"Bergmann","year":"2012","journal-title":"Basic Clin. Pharma Tox"},{"key":"B12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3109\/0284186X.2012.707787","article-title":"GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients","volume":"52","author":"Bergmann","year":"2013","journal-title":"Acta Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2015.06.056","article-title":"Association of the Charcot\u2013Marie\u2013Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance)","volume":"357","author":"Boora","year":"2015","journal-title":"J. Neurological Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2217\/pgs.14.127","article-title":"Snps and taxane toxicity in breast cancer patients","volume":"15","author":"Bos\u00f3","year":"2014","journal-title":"Pharmacogenomics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/2049463714542605","article-title":"Pain in cancer survivors","volume":"8","author":"Brown","year":"2014","journal-title":"Br. J. Pain"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s11064-016-2007-9","article-title":"Genetic susceptibility to Bortezomib-Induced peripheral neuroropathy: replication of the reported candidate susceptibility loci","volume":"42","author":"Campo","year":"2017","journal-title":"Neurochem. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/hon.2391","article-title":"Bortezomib\u2010induced peripheral neuropathy: a genome\u2010wide association study on multiple myeloma patients","volume":"36","author":"Campo","year":"2018","journal-title":"Hematol. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","article-title":"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies","volume":"51","author":"Cavaletti","year":"2010","journal-title":"Leukemia and Lymphoma"},{"key":"B20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/tpj.2012.31","article-title":"A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil\/leucovorin\/oxaliplatin (FOLFOX4) regimen","volume":"13","author":"Cecchin","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1007\/s00520-019-04987-8","article-title":"Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview","volume":"27","author":"Chan","year":"2019","journal-title":"Support. Care Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/bioinformatics\/btn653","article-title":"SNPnexus: a web database for functional annotation of newly discovered and public domain single nucleotide polymorphisms","volume":"25","author":"Chelala","year":"2009","journal-title":"Bioinformatics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1349-7006.2009.01418.x","article-title":"Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX\u20104 treatment in Asian patients with colorectal carcinoma","volume":"101","author":"Chen","year":"2010","journal-title":"Cancer Science"},{"key":"B24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2217\/pgs-2020-0053","article-title":"Genetic variation in charcot\u2013marie\u2013tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy","volume":"21","author":"Chen","year":"2020","journal-title":"Pharmacogenomics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cancergencyto.2009.12.004","article-title":"Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma","volume":"198","author":"Cho","year":"2010","journal-title":"Cancer Genet. Cytogenet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1007\/s00277-024-05973-9","article-title":"An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma","volume":"103","author":"Christofyllakis","year":"2024","journal-title":"Ann. Hematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/sj.bjc.6605239","article-title":"Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer","volume":"101","author":"Chua","year":"2009","journal-title":"Br. J. Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/cpt.1958","article-title":"Genomewide meta\u2010analysis validates a role for S1PR1 in microtubule targeting agent\u2010induced sensory peripheral neuropathy","volume":"108","author":"Chua","year":"2020","journal-title":"Clin Pharma Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5195\/jmla.2020.834","article-title":"Improving the translation of search strategies using the polyglot search translator: a randomized controlled trial","volume":"108","author":"Clark","year":"2020","journal-title":"Jmla"},{"key":"B30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.critrevonc.2017.09.009","article-title":"The molecular genetics of chemotherapy\u2013induced peripheral neuropathy: a systematic review and meta-analysis","volume":"120","author":"Cliff","year":"2017","journal-title":"Crit. Rev. Oncology\/Hematology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.3324\/haematol.2011.041434","article-title":"Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients","volume":"96","author":"Corthals","year":"2011","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mdt546","article-title":"Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study","volume":"25","author":"Custodio","year":"2014","journal-title":"Ann. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.1093\/nar\/gks364","article-title":"SNPnexus: a web server for functional annotation of novel and publicly known genetic variants (2012 update)","volume":"40","author":"Dayem Ullah","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/bib\/bbt004","article-title":"A practical guide for the functional annotation of genetic variations using SNPnexus","volume":"14","author":"Dayem Ullah","year":"2013","journal-title":"Briefings Bioinforma."},{"key":"B36","doi-asserted-by":"publisher","first-page":"W109","DOI":"10.1093\/nar\/gky399","article-title":"SNPnexus: assessing the functional relevance of genetic variation to facilitate the promise of precision medicine","volume":"46","author":"Dayem Ullah","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1158\/1078-0432.CCR-12-3786","article-title":"CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity","volume":"19","author":"De Graan","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/genes14010170","article-title":"Association between genetic variants and peripheral neuropathy in patients with NSCLC treated with first-line platinum-based therapy","volume":"14","author":"De Jong","year":"2023","journal-title":"Genes"},{"key":"B39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bcpt.13866","article-title":"Toxicity and therapy outcome associations in LIG3, SLCO1B3, ABCB1, OPRM1 and GSTP1 in high\u2010grade serous ovarian cancer","volume":"132","author":"Deng","year":"2023","journal-title":"Basic Clin. Pharma Tox"},{"key":"B40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2015.0894","article-title":"Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia","volume":"313","author":"Diouf","year":"2015","journal-title":"JAMA"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1158\/1078-0432.ccr-16-3224","article-title":"Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer","volume":"23","author":"Dolan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/pbc.22845","article-title":"Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia","volume":"56","author":"Egbelakin","year":"2011","journal-title":"Pediatr. Blood and Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/bja\/aet208","article-title":"Neuropathic pain in cancer","volume":"111","author":"Fallon","year":"2013","journal-title":"Br. Journal Anaesthesia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/hon.2337","article-title":"Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array","volume":"35","author":"Garc\u00eda-Sanz","year":"2017","journal-title":"Hematol. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00280-011-1745-2","article-title":"Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity","volume":"68","author":"Guilhaumou","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1200\/JCO.2013.52.4629","article-title":"Pain in cancer survivor","volume":"32","author":"Glare","year":"2014","journal-title":"J. Clinical Oncology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/s41375-021-01484-y","article-title":"Association between CEP72 genotype and persistent neuropathy in survivors of childhood acute lymphoblastic leukemia","volume":"36","author":"Goodenough","year":"2022","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41397-017-0003-3","article-title":"Mir-pharmacogenetics of vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia","volume":"18","author":"Gutierrez-Camino","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.4103\/jfmpc.jfmpc_580_21","article-title":"A review of the neurological complications of breast cancer","volume":"11","author":"Hekmatnia","year":"2022","journal-title":"J. Fam. Med. Prim. Care"},{"key":"B49","doi-asserted-by":"publisher","first-page":"8097","DOI":"10.1158\/1078-0432.CCR-05-1152","article-title":"Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel","volume":"11","author":"Henningsson","year":"2005","journal-title":"Clin. Cancer Research"},{"key":"B50","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10549-012-2054-0","article-title":"CYP2C8*3 predicts benefit\/risk profile in breast cancer patients receiving neoadjuvant paclitaxel","volume":"134","author":"Hertz","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/annonc\/mdt018","article-title":"CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel","volume":"24","author":"Hertz","year":"2013","journal-title":"Ann. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00280-010-1425-7","article-title":"Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis","volume":"67","author":"Hong","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12967-022-03754-4","article-title":"Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study","volume":"20","author":"Hooshmand","year":"2022","journal-title":"J. Transl. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jns.2014.12.041","article-title":"Candidate pathway-based genetic association study of platinum and platinum\u2013taxane related toxicity in a cohort of primary lung cancer patients","volume":"349","author":"Johnson","year":"2015","journal-title":"J. Neurological Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11764-014-0379-x","article-title":"Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer","volume":"9","author":"Jones","year":"2015","journal-title":"J. Cancer Surviv"},{"key":"B56","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.canep.2010.02.008","article-title":"Associations between glutathione S-transferase \u03c0 Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy","volume":"34","author":"Kanai","year":"2010","journal-title":"Cancer Epidemiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/annonc\/mdw074","article-title":"Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN trial)","volume":"27","author":"Kanai","year":"2016","journal-title":"Ann. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.annonc.2021.08.1745","article-title":"Large-scale prospective genome-wide association study of oxaliplatin in stage II\/III colon cancer and neuropathy","volume":"32","author":"Kanai","year":"2021","journal-title":"Ann. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.3892\/ol.2019.9907","article-title":"GSTP1 as a potential predictive factor for adverse events associated with platinum-based antitumor agent-induced peripheral neuropathy","volume":"17","author":"Katayanagi","year":"2019","journal-title":"Oncol. Lett"},{"key":"B60","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1182\/blood-2006-10-054528","article-title":"Ancestry and pharmacogenetics of antileukemic drug toxicity","volume":"109","author":"Kishi","year":"2007","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1111\/bcp.15267","article-title":"Contribution of common and rare genetic variants in CEP72 on vincristine\u2010induced peripheral neuropathy in brain tumour patients","volume":"88","author":"Klumpers","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1158\/1078-0432.CCR-15-0133","article-title":"Pharmacoethnicity in paclitaxel-induced sensory peripheral neuropathy","volume":"21","author":"Komatsu","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3109\/0284186X.2014.985388","article-title":"RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial Alliance N08C1","volume":"54","author":"Kulkarni","year":"2015","journal-title":"Acta Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3892\/ol.2013.1467","article-title":"Polymorphisms of GSTP1, ERCC2 and TS-3\u2032UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients","volume":"6","author":"Kumamoto","year":"2013","journal-title":"Oncol. Lett."},{"key":"B65","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.2147\/OTT.S106574","article-title":"Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel","volume":"9","author":"Kus","year":"2016","journal-title":"OncoTargets Therapy"},{"key":"B66","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ejca.2008.10.015","article-title":"Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients","volume":"45","author":"Kweekel","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1111\/j.1349-7006.2009.01186.x","article-title":"Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX\u20104 treatment in Asian patients with colorectal carcinoma","volume":"100","author":"Lai","year":"2009","journal-title":"Cancer Sci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40360-015-0001-5","article-title":"Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer","volume":"16","author":"Lambrechts","year":"2015","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/jmedgenet-2012-101466","article-title":"Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy","volume":"50","author":"Leandro-Garc\u00eda","year":"2013","journal-title":"J. Med. Genet."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-05-2076","article-title":"Glutathione S -Transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy","volume":"12","author":"Lecomte","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/tpj.2010.13","article-title":"Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity","volume":"11","author":"Leskel\u00e4","year":"2011","journal-title":"Pharmacogenomics J."},{"key":"B72","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1158\/1078-0432.CCR-15-3163","article-title":"A genome-wide association study identifies a novel locus for Bortezomib-Induced peripheral neuropathy in European patients with multiple myeloma","volume":"22","author":"Magrangeas","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1186\/s12885-018-4728-4","article-title":"Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients","volume":"18","author":"Mahmoudpour","year":"2018","journal-title":"BMC Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1200\/JCO.2006.10.4752","article-title":"Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer","volume":"25","author":"Marsh","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41397-019-0081-5","article-title":"Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia","volume":"19","author":"Martin-Guerrero","year":"2019","journal-title":"Pharmacogenomics J."},{"key":"B76","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1200\/JCO.2009.21.7943","article-title":"Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from north American gastrointestinal intergroup trial N9741","volume":"28","author":"McLeod","year":"2010","journal-title":"JCO"},{"key":"B77","doi-asserted-by":"publisher","first-page":"104552","DOI":"10.1016\/j.jpain.2024.104552","article-title":"Genetic risk factors for bortezomib-induced neuropathic pain in an Asian population: a genome-wide association study in South Korea","volume":"25","author":"Min","year":"2024","journal-title":"J. Pain"},{"key":"B78","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/j.1440-1754.2011.02103.x","article-title":"Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited\u2010sampling, population modelling approach","volume":"47","author":"Moore","year":"2011","journal-title":"J. Paediatr. Child. Health"},{"key":"B79","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41525-024-00443-7","article-title":"Genomic variations associated with risk and protection against vincristine-induced peripheral neuropathy in pediatric cancer patients","volume":"9","author":"Mufti","year":"2024","journal-title":"Npj Genom Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.21873\/anticanres.17326","article-title":"Association between ABCC2 \u221224C>T and nab-paclitaxel-induced peripheral neuropathy in Japanese patients with pancreatic cancer","volume":"44","author":"Nakayama","year":"2024","journal-title":"Anticancer Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"W185","DOI":"10.1093\/nar\/gkaa420","article-title":"SNPnexus: a web server for functional annotation of human genome sequence variation (2020 update)","volume":"48","author":"Oscanoa","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/annonc\/mdx491","article-title":"Clinical and genetic predictors of paclitaxel neurotoxicity based on patient-versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial","volume":"28","author":"Park","year":"2017","journal-title":"Ann. Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10549-010-1034-5","article-title":"Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients","volume":"124","author":"Rizzo","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"B85","first-page":"69","article-title":"TRPV1 receptors and signal transduction","volume-title":"TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades","author":"Rosenbaum","year":"2007"},{"key":"B86","doi-asserted-by":"publisher","first-page":"6828","DOI":"10.1038\/srep06828","article-title":"Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients","volume":"4","author":"Ruzzo","year":"2014","journal-title":"Sci. Rep."},{"key":"B87","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s43440-020-00109-y","article-title":"Chemotherapy-induced peripheral neuropathy: part 1\u2014current state of knowledge and perspectives for pharmacotherapy","volume":"72","author":"Sa\u0142at","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"B88","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/pbc.23192","article-title":"Germline genetic variation and treatment response on CCG\u20101891","volume":"58","author":"Sepe","year":"2012","journal-title":"Pediatr. Blood and Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"B90","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.ejca.2006.06.017","article-title":"Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia","volume":"42","author":"Sissung","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12863-015-0211-2","article-title":"Assessing the quality of published genetic association studies in meta-analyses: the quality of genetic studies (Q-Genie) tool","volume":"16","author":"Sohani","year":"2015","journal-title":"BMC Genetics"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e010403","DOI":"10.1136\/bmjopen-2015-010403","article-title":"Empirical evaluation of the Q-Genie tool: a protocol for assessment of effectiveness","volume":"6","author":"Sohani","year":"2016","journal-title":"BMJ Open"},{"key":"B94","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of chemotherapy-induced peripheral neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/FPC.0000000000000318","article-title":"Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci","volume":"28","author":"Sucheston-Campbell","year":"2018","journal-title":"Pharmacogenetics Genomics"},{"key":"B112","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s10549-011-1671-3","article-title":"Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)","volume":"130","author":"Sucheston","year":"2011","journal-title":"Breast Cancer Res. Treat"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12885-020-06834-0","article-title":"Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients","volume":"20","author":"Tanabe","year":"2020","journal-title":"BMC Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1015746","DOI":"10.3389\/fmolb.2022.1015746","article-title":"Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients","volume":"9","author":"Tay","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/jns.12110","article-title":"Genetic determinants of chronic oxaliplatin\u2010induced peripheral neurotoxicity: a genome\u2010wide study replication and meta\u2010analysis","volume":"20","author":"Terrazzino","year":"2015","journal-title":"J. Peripher. Nerv. Sys"},{"key":"B100","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.3390\/cancers14143510","article-title":"Genetic polymorphisms associated with vincristine pharmacokinetics and vincristine-induced peripheral neuropathy in pediatric oncology patients","volume":"14","author":"Van De Velde","year":"2022","journal-title":"Cancers"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1352939","DOI":"10.3389\/fphar.2024.1352939","article-title":"NeuroPredict: study of the predictive value of ABCB1 genetic polymorphisms and associated clinical factors in chronic chemotherapy-induced peripheral neuropathy (CIPN)","volume":"15","author":"Vargas-Aliaga","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/toxics3020152","article-title":"Taxane-induced peripheral neurotoxicity","volume":"3","author":"Velasco","year":"2015","journal-title":"Toxics"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e2400199","DOI":"10.1200\/GO.24.00199","article-title":"Elevating cancer care standards worldwide: an analysis of global initiatives and progress","volume":"10","author":"Wiernik","year":"2024","journal-title":"JCO Glob. Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1002\/cncr.26614","article-title":"Polymorphic markers associated with severe oxaliplatin\u2010induced, chronic peripheral neuropathy in colon cancer patients","volume":"118","author":"Won","year":"2012","journal-title":"Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/ije\/dyaa149","article-title":"Let\u2019s call it the effect allele: a suggestion for GWAS naming conventions","volume":"49","author":"Wootton","year":"2020","journal-title":"Int. J. Epidemiol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/cpt.1179","article-title":"Pharmacogenomics of vincristine\u2010induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes","volume":"105","author":"Wright","year":"2019","journal-title":"Clin Pharma Ther."},{"key":"B107","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41397-022-00282-8","article-title":"A machine learning model using SNPs obtained from a genome-wide association study predicts the onset of vincristine-induced peripheral neuropathy","volume":"22","author":"Yamada","year":"2022","journal-title":"Pharmacogenomics J."},{"key":"B108","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s13046-021-02141-z","article-title":"Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development","volume":"40","author":"Yang","year":"2021","journal-title":"J. Exp. and Clin. Cancer Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/cpt.3462","article-title":"Pharmacokinetic, pharmacodynamic and pharmacogenetic studies related to vincristine-induced peripheral neuropathy in Chinese pediatric ALL patients","volume":"117","author":"Yuan","year":"2025","journal-title":"Clin. Pharma. Therapeutics"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zaj\u0105czkowska","year":"2019","journal-title":"IJMS"},{"key":"B110","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/FPC.0000000000000345","article-title":"Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study","volume":"28","author":"Zgheib","year":"2018","journal-title":"Pharmacogenetics Genomics"},{"key":"B111","doi-asserted-by":"publisher","first-page":"955","DOI":"10.32604\/or.2023.043922","article-title":"A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients","volume":"32","author":"Zhang","year":"2024","journal-title":"OR"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1842379\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:34:10Z","timestamp":1783575250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1842379\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":113,"alternative-id":["10.3389\/fphar.2026.1842379"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1842379","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1842379"}}